Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the market in 2028. #pharma #biospace https://t.co/bgytxbJtGU

Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news. #biotech #RNA #biospace https://t.co/sQcxY1eLkY

The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for clinical differentiation” in obesity. #obesity #pharma #biospace https://t.co/UHmh5GuJ1q

Boston-based @nchromabio is parting ways with an undisclosed number of employees as it shifts its pipeline priorities. Learn more in our layoff tracker. #layoffs #biopharma #biospace https://t.co/7VFRzcYjam

Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 combined jobs hit just 13% of that target in 2024. Ten awardees had reported layoffs last year, including Charles River Laboratories and @moderna_tx.

While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts are optimistic a turnaround could start sooner. They discuss early signals of recovery and challenges that remain. #jobmarket #biopharma #biospace

Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts agree, needs to take control of the narrative. #editorial #FDA #Pharma #biospace https://t.co/E500bf3hgs

In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis. #layoffs #ALS #pharma #biospace https://t.co/5b2yz5qtQm

Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2. #neuroscience #pharma #biospace https://t.co/IBIAXUwr6a

The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed. #rarediseases #genetherapy #biospace https://t.co/zX56KEChO9

The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to disclose priority indications. #biotech #pharma #biospace https://t.co/cGWnr7QWDT

In this episode presented by Slone Partners, Leslie Loveless, Co-CEO and Managing Partner discusses how hiring and the building of executive teams has responded to the current biotech environment. #biotech #podcast #funding #hiring #biospace https://t.co/0ShN0QPko4

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth disorder. #FDA #pharma #biospace https://t.co/6XdfiLWhsI

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive. #FDA #funding #pharma #biospace https://t.co/IvQu3Et9py

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences. #drugdevelopment #pharma #biotech #AI #biospace https://t.co/C8intJFKSH

The strategic initiative will extend Metagenomi’s cash runway into the fourth quarter of 2027. That same year, the company expects to generate initial Phase I data for its lead asset MGX-001 in hemophilia A. #layoffs #pharma #biospace https://t.co/aZ3hxVtj6m

Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class tolerability,” according to analysts at H.C. Wainwright. #pharma #biospace https://t.co/VmBZXVMcyC

Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections. #investors #pharma #biotech #biospace https://t.co/GIpVBttL6P

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive. #immunology #pharma #biospace https://t.co/Z69o05tODG

With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those announced to much fanfare from the White House, will result in meaningful reductions